文献速递白血病淋巴瘤

iFCG方案治疗IGHV突变且无TP53异常的慢性淋巴细胞白血病

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
PubMed 文献 · Leukemia · 2021-05-18

这项II期试验纳入45例既往未治疗的IGHV突变且无del(17p)/TP53突变的CLL患者,接受3周期iFCG(伊布替尼、氟达拉滨、环磷酰胺、奥妥珠单抗)后,根据骨髓U-MRD状态决定后续治疗;中位随访41.3个月,3年PFS和OS均为98%,无CLL进展,方案为限时治疗。

要点

  • 3周期iFCG后87%达骨髓U-MRD,12周期后91%,最佳U-MRD率98%。
  • 3年PFS和OS均为98%,无患者出现CLL进展。
  • 3-4级中性粒细胞减少和血小板减少发生率分别为58%和40%。

核心结论

  • 含3周期化疗的iFCG方案对IGHV突变且无del(17p)/TP53突变的CLL有效且为限时治疗。

研究设计与样本

  • II期试验,纳入45例既往未治疗的IGHV突变且无del(17p)/TP53突变的CLL患者。

主要发现

  • 3周期后38%达CR/CRi,87%达骨髓U-MRD;12周期后分别为67%和91%。
  • 最佳骨髓U-MRD率为98%(44/45),无患者出现CLL进展。
  • 3年PFS和OS均为98%,中位随访41.3个月。
  • 3-4级中性粒细胞减少和血小板减少分别发生于58%和40%的患者。

关键数值与推荐

  • 3周期后达CR/CRi且骨髓U-MRD者接受9周期伊布替尼+3周期奥妥珠单抗,其余接受9周期伊布替尼+奥妥珠单抗。
  • 完成12周期者均按试验设计停用伊布替尼。

临床怎么用

  • 对IGHV突变且无del(17p)/TP53突变的CLL患者,iFCG可作为含3周期化疗的限时方案。
  • 根据3周期后骨髓U-MRD和缓解状态调整后续治疗强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previously untreated patients with CLL with mutated IGHV and absence of del(17p)/TP53 mutation. Patients received ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for three cycles. Patients who achieved complete remission (CR)/CR with incomplete count recvoery (CRi) with marrow undetectable measurable residual disease (U-MRD) received additional nine cycles of ibrutinib with three cycles of obinutuzumab; all others received nine additional cycles of ibrutinib and obinutuzumab. Patients in marrow U-MRD remission after cycle 12 discontinued all treatment, including ibrutinib. Forty-five patients were treated. The median follow-up is 41.3 months. Among the total 45 treated patients, after three cycles, 38% achieved CR/CRi and 87% achieved marrow U-MRD. After cycle 12, the corresponding numbers were 67% and 91%, respectively. Overall, 44/45 (98%) patients achieved marrow U-MRD as best response. No patient had CLL progression. The 3-year progression-free survival (PFS) and overall survival (OS) were 98% and 98%, respectively. Per trial design, all patients who completed cycle 12 discontinued ibrutinib, providing for a time-limited therapy. Grade 3-4 neutropenia and thrombocytopenia occurred in 58% and 40% patients, respectively. The iFCG regimen with only 3 cycles of chemotherapy is an effective, time-limited regimen for patients with CLL with mutated IGHV and without del(17p)/TP53 mutation.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jain N, Thompson P, Burger J, et al. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021. PMID: 34007049. doi:10.1038/s41375-021-01280-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。